BAM
ADCT icon

Belpointe Asset Management’s ADC Therapeutics ADCT Stock Holding History

Belpointe Asset Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,724
Closed -$6.62K – 3721
2022
Q4 		$6.62K Buy
+1,724
New +$6.89K ﹤0.01% 2819

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Belpointe Asset Management's ADCT Position: Q1 2023 in Review

Belpointe Asset Management sold out of ADC Therapeutics (ADCT) in Q1 2023, closing a stake of 1,724 shares — an estimated $6.62K sold.

Belpointe Asset Management first reported a position in ADCT in Q4 2022 and held it in 1 quarter. The position peaked at $6.62K in Q4 2022. 59 funds tracked by Wall St. Rank hold ADCT as of Q1 2023.

  • Belpointe Asset Management reported no remaining ADC Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 1,724 ADC Therapeutics shares in Q1 2023, an estimated $6.62K.
  • Belpointe Asset Management first reported a position in ADC Therapeutics in Q4 2022 and held it in 1 quarter.
  • Belpointe Asset Management's ADC Therapeutics position peaked at $6.62K in Q4 2022.
  • 59 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2023.

Based on Belpointe Asset Management's 13F filing for Q1 2023, filed 15 May 2023.